Buckingham Strategic Partners Inmune Bio, Inc. Transaction History
Buckingham Strategic Partners
- $8.25 Billion
- Q3 2025
A detailed history of Buckingham Strategic Partners transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 40,950 shares of INMB stock, worth $59,377. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,950
Previous 48,813
16.11%
Holding current value
$59,377
Previous $112,000
24.11%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding INMB
# of Institutions
85Shares Held
5.36MCall Options Held
310KPut Options Held
371K-
Vanguard Group Inc Valley Forge, PA876KShares$1.27 Million0.0% of portfolio
-
Black Rock Inc. New York, NY813KShares$1.18 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$864,73945.87% of portfolio
-
Geode Capital Management, LLC Boston, MA469KShares$680,6880.0% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL369KShares$535,6850.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $26M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...